We are live on ! Find out more
XDNA

Strategic Trust Kelly CRISPR & Gene Editing Technology ETF
XDNA

Delisted

XDNA was delisted on the 30th of November, 2023.

Back to rankings

1 hedge funds and large institutions have $137K invested in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

51% less capital invested

Capital invested by funds: $279K → $137K (-$142K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$74.7K
2
UBS Group
UBS Group
Switzerland
-$53.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$137K -$74.7K -7,307 -32%
UBS Group
2
UBS Group
Switzerland
– -$53.2K -5,352 Closed

XDNA Hedge Fund Activity: Q1 2023 in Review

1 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) for Q1 2023, worth a combined $137K — down 51% from $279K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of XDNA and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was Citadel Advisors, cutting an estimated $74.7K.

  • 1 institutional investor held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) as of Q1 2023, down from 2 in Q4 2022.
  • Funds reported $137K of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF stock for Q1 2023, down 51% quarter-over-quarter.
  • 0 funds opened new Strategic Trust Kelly CRISPR & Gene Editing Technology ETF positions in Q1 2023 and 1 closed out, a net change of -1 holder.
  • The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF seller in Q1 2023 was Citadel Advisors, an estimated $74.7K sold.

Based on aggregated 13F filings for Q1 2023.